EXCLUSIVE REPORT: How the pharma industry is strategizing for generative AI
With this report including responses from over 4000 pharma respondents, we can regard this industry as one of the fastest-moving in terms of its investments in and implementation of generative AI.
Here’s a sneak peak of some of the data and insights from the whitepaper: 
  • 84% larger business (annual revenues > $1 billion) are using or plan to use generative AI in next 12 months
  • IT, software development, data analytics and cybersecurity functions implement generative AI as the early adaptor
  • Innovation and R&D departments look forward to implementing Generative AI internally
  • Microsoft, OpenAI, Google and AWS have a strong hold over the vendor landscape today 
Kind regards,

Download your exclusive report here
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: https://www.thomsonreuters.com/en/privacy-statement.html.
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.